PPCBNasdaqPharmaceutical PreparationsFiscal year ends June 30
Propanc Biopharma, Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026
$0.32−0.03 (-7.31%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$39.1830 (−99.20%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$18.86M
- EPS, diluted
- -$17.62
- Free cash flow
- -$5.69M
Fifteen years at a glance
Fiscal years 2012 to 2026, USD
Operating income
-$18.19M
Net income
-$18.86M
EPS, diluted
-$17.62
Free cash flow
-$5.69M
Reported period